Sogroya® is the first and only once-weekly growth hormone (GH) treatment for both children and adults with growth hormone deficiency (GHD).
Actor portrayal
In a 1-year (52-week) study of 200 children who had never been treated for growth hormone deficiency (GHD), Sogroya® was compared with a daily GH treatment (somatropin).a
Children taking Sogroya® grew 4.4 inches (11.2 cm), on average, at 1 year.
Children taking daily GH grew 4.6 inches (11.7 cm), on average, at 1 year.
aThe main goal of this study was to see if children who took Sogroya® once per week grew at the same rate as children who took the daily GH treatment.
The most common side effects of Sogroya® in children include:
The most common side effects of Sogroya® in adults include:
6.1% of children taking Sogroya® experienced injection-site reactions, which included:
1.5% injection-site pain
1.5% injection-site bruising
1.5% injection-site hematoma
0.8% injection-site reaction
0.8% injection-site swelling
Talk to your doctor or your child’s doctor for medical advice about these and other possible side effects.
According to the Growth Hormone Research Society, a once-weekly GH option may offer patients and families flexibility and a therapeutic alternative.
Actor portrayal
Connect with us to get the latest news about once-weekly Sogroya®
Updates and helpful information
Tips and suggestions
Support, including patient resources
Learn about the Sogroya® difference
Are you ready to learn what makes Sogroya® different?
Explore the science behind Sogroya®
The path to fewer injection days with Sogroya® starts with albumin-binding prolongation technology.